Kura Oncology, Inc. - KURA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Montanova Capital, LLC | 9.7% | 8,575,422 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Averill Master Fund, Ltd. | 8.8% | 7,805,540 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Aaron Cowen | 9.7% | 8,575,422 | View |
| May 15, 2026 | SCHEDULE 13G/A | Armistice Capital, LLC | 4.23% | 3,736,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Steven Boyd | 4.23% | 3,736,000 | View |
| Apr 30, 2026 | SCHEDULE 13G | Vanguard Capital Management | 5.01% | 4,428,812 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.